Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Article

cited authors

  • Lee, Eudocia Q; Kuhn, John; Lamborn, Kathleen R; Abrey, Lauren; DeAngelis, Lisa M; Lieberman, Frank; Robins, H Ian; Chang, Susan M; Yung, WK Alfred; Drappatz, Jan; Mehta, Minesh P; Levin, Victor A; Aldape, Kenneth; Dancey, Janet E; Wright, John J; Prados, Michael D; Cloughesy, Timothy F; Gilbert, Mark R; Wen, Patrick Y

fiu authors

publication date

  • December 1, 2012

keywords

  • ANTITUMOR-ACTIVITY
  • CCI-779
  • Clinical Neurology
  • GLIOMA
  • Life Sciences & Biomedicine
  • MULTIFORME
  • Neurosciences & Neurology
  • Oncology
  • RADIOTHERAPY
  • RAPAMYCIN
  • Science & Technology
  • TEMOZOLOMIDE
  • TRIAL
  • anaplastic glioma
  • glioblastoma
  • malignant glioma
  • sorafenib
  • temsirolimus

Digital Object Identifier (DOI)

start page

  • 1511

end page

  • 1518

volume

  • 14

issue

  • 12